Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.44
3.87
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Jacobio Pharmaceuticals Group Co Ltd
Net Income (Common)
Jacobio Pharmaceuticals Group Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
|
Net Income (Common)
-ÂĄ359.1m
|
CAGR 3-Years
38%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
||
Beigene Ltd
HKEX:6160
|
Net Income (Common)
-ÂĄ6.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Net Income (Common)
ÂĄ2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Net Income (Common)
ÂĄ1.2B
|
CAGR 3-Years
23%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Net Income (Common)
ÂĄ1.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Net Income (Common)
ÂĄ3.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
12%
|
CAGR 10-Years
39%
|
Jacobio Pharmaceuticals Group Co Ltd
Glance View
Jacobio Pharmaceuticals Group Co., Ltd. operates as an investment holding company which engages in research and development of new drugs. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-12-21. The firm is primarily responsible for the independent discovery and development of innovative tumor therapies. The firm's main drug development projects include JAB-3068 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The firm mainly conducts business within the domestic market.
See Also
What is Jacobio Pharmaceuticals Group Co Ltd's Net Income (Common)?
Net Income (Common)
-359.1m
CNY
Based on the financial report for Dec 31, 2023, Jacobio Pharmaceuticals Group Co Ltd's Net Income (Common) amounts to -359.1m CNY.
What is Jacobio Pharmaceuticals Group Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-19%
Over the last year, the Net Income (Common) growth was 3%. The average annual Net Income (Common) growth rates for Jacobio Pharmaceuticals Group Co Ltd have been 38% over the past three years , -19% over the past five years .